H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Zymeworks (NYSE:ZYME) Inc on Tuesday, setting a price target of $60, which is approximately 66.76% above the present share price of $35.98.
Chattopadhyay expects Zymeworks Inc to post earnings per share (EPS) of -$0.64 for the third quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Zymeworks, with an average price target of $54.42.
The analysts price targets range from a high of $70 to a low of $37.67.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $8.27 million and a net profit of -$35.88 million. The company's market cap is $1.69 billion.
According to TipRanks.com, H.C. Wainwright analyst Debjit Chattopadhyay is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.3% and a 53.07% success rate.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.